A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7 Meeting Abstract
| Authors: | Passaro, A.; Girard, N.; Rodriguez Abreu, D.; Gumus, M.; Wu, Y. L.; Syrigos, K.; Ramlau, R.; Santos, E.; Berz, D.; Gandhi, C.; Vokes, N.; Wang, B.; Rotow, J.; Paik, P.; Weiss, J.; Agulnik, J.; Bai, X.; McGovern, P.; Calles Blanco, A. |
| Abstract Title: | A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7 |
| Meeting Title: | European Lung Cancer Congress (ELCC) 2025 |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 20 |
| Issue: | 3 Suppl. 1 |
| Meeting Dates: | 2025 Mar 26-29 |
| Meeting Location: | Paris, France |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-03-01 |
| Start Page: | S94 |
| End Page: | S95 |
| DOI: | 10.1016/s1556-0864(25)00328-4 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meet Abstract: 133TiP -- Source: Cinahl |
